Blood-Based Neuroendocrine Tumor mRNA Signature Identifies Residual Disease and at Day 30 after Operation Predicts Tumor Recurrence with 98% Specificity

2020 ◽  
Vol 231 (4) ◽  
pp. e53
Author(s):  
Irvin M. Modlin ◽  
Mark Kidd ◽  
Massimo Falconi ◽  
Andrea Frilling ◽  
Anna Malczewska ◽  
...  
2021 ◽  
pp. 90-97
Author(s):  
Pak Chiu Wong ◽  
Wong Hoi She ◽  
Ui Soon Khoo ◽  
Tan To Cheung

We report an unusual presentation of primary hepatic neuroendocrine tumor which was initially misdiagnosed as intrahepatic cholangiocarcinoma. The diagnosis was only revealed after a major liver resection by histopathology. With adjuvant lanreotide injection, the patient survived for more than 16 months after the operation without tumor recurrence. Diagnosis of this rare tumor has been a major challenge and we emphasize the importance of a preoperative diagnosis. Surgical resection remains the mainstay for curative treatment, while peptide receptor radionuclide therapy is an emerging treatment option which has provided promising results.


2021 ◽  
Author(s):  
Qi Yu ◽  
Zhen Li ◽  
Xinwei Han

Abstract Neuroendocrine tumors in the mediastinum are relatively rare. We report a patient with mediastinal neuroendocrine tumor that was successfully resected after descending stage by drug-eluting embolic transcatheter arterial chemoembolization had been performed. No tumor recurrence was found in the 1-year follow-up after surgical resection.


2020 ◽  
Vol 31 (2) ◽  
pp. 202-212 ◽  
Author(s):  
K. Öberg ◽  
A. Califano ◽  
J.R. Strosberg ◽  
S. Ma ◽  
U. Pape ◽  
...  

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 442-442
Author(s):  
Yi-Zarn Wang ◽  
Aman Chauhan ◽  
Robert A Ramirez ◽  
Melissa A Stevens ◽  
J Philip Boudreaux ◽  
...  

442 Background: Midgut neuroendocrine tumor (NET) patients are often diagnosed at an advanced stage with extensive mesenteric lymph node and liver metastasis. The only treatment for potential cure and durable results is resection with extensive debulking. However, even with the most elegant surgical dissection/resection, macro and microscopic residual disease at the tumor resection bed remains a distinctive possibility. We hypothesize that local application of 5-florouracil (5-FU) within tumor bed would eliminate the microscopic residual disease post operatively. Methods: Surgical records of 188 consecutive patients who underwent extensive cytoreductive surgeries for stage IV, small bowel NETs with boggy mesenteric lymphadenopathy between 2003-2012 were reviewed. 85 Patients who had 5-Florouracil saturated gelfoam strips secured into their mesenteric resection defects served as the study group (n=85) with one hundred three patients who did not receive such intra-operative chemotherapy as the control (n=103). Survival from the time of diagnosis, postoperative morbidity and mortality between the two groups were collected and compared. Results: Mortality rates at immediate, 30, 60 and 90 days post operative period were 3; 0; 1; 0; and 0; 2; 0; 4 respectively for study and control group. Minor complications (Clavien-Dindo Grade I and II) at 30, 60 and 90 day postoperative period were 12; 0; 1 and 12; 5; 5 respectively. Major complications (Grade III and IV) at the same time intervals were 2; 0; 2 and 2; 3; 2 for study and control groups. Most of all, the mean survival from time of histological diagnosis for the study patients was 210 months (17.5 years) as compared to 177 months (14.7 years) for the control group with a difference of 33 months (2.75 years). Conclusions: Intra-operative tumor resection bed chemotherapy is a safe adjuvant without any discernible toxicity. Furthermore, it might provide survival benefit to midgut NET patients with extensive mesenteric lymphadenopathy undergoing extensive cytoreductive surgery without additional procedure related complications.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Irvin M. Modlin ◽  
Mark Kidd ◽  
Andrea Frilling ◽  
Massimo Falconi ◽  
Pier Luigi Filosso ◽  
...  

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Sricharan Gopakumar ◽  
Joy Gumin ◽  
Marc Daou ◽  
Daniel Ledbetter ◽  
Brittany Parker Kerrigan ◽  
...  

Abstract INTRODUCTION Current treatments for glioblastoma (GBM) are minimally effective and the prognosis for patients is uniformly poor despite multimodal therapy. While prior studies have examined intratumoral injection of oncolytic virus DNX-2401 into recurrent tumor, the potential of DNX-2401 delivered into the surgical resection cavity using tumor-tropic human mesenchymal stem cells (MSCs) has not been evaluated. We hypothesize that using a fibrin scaffold for transplanting MSCs loaded with DNX-2401 (MSCs-DNX-2401) into the resection cavity will improve MSC and viral delivery, kill residual tumor cells, decrease GBM recurrence, and improve overall survival. METHODS MSCs-DNX-2401 were either seeded in fibrin or suspended in PBS and placed in the upper wells of a transwell with U87 tumor cells plated below. After 1 wk, U87 cells were counted to compare rates of cellular killing to evaluate release of DNX-2401 from fibrin-seeded MSCs. U87 tumor cells were then transduced with mCherry-Luciferase and implanted in 20 mice. Fluorescence-guided surgical resection of glioma xenografts was performed on day 10. Either MSCs (control) or MSCs-DNX-2401 (treatment) were seeded in fibrin and implanted in the resection cavity. Postoperative bioluminescence imaging was used to evaluate extent of residual disease and weekly serial imaging was used to monitor tumor recurrence in each group. RESULTS Transwell experiments demonstrate significant cytotoxic killing of U87 tumor cells with MSCs-DNX-2401 seeded in fibrin having comparable oncolytic activity to MSC-DNX-2401 without fibrin. In vivo studies show four mice in the treatment group (40%) demonstrating complete responses to delivery of MSCs-DNX-2401 using fibrin. Kaplan-Meier survival analysis demonstrates survival benefit with prolonged median and overall survival in the treatment group (P < .05). CONCLUSION This translational study validates the overall treatment paradigm for delivering oncolytic virotherapy into the tumor resection cavity using MSCs seeded in fibrin to decrease tumor recurrence and prolong overall survival. This project represents an important preliminary step for eventual application of this technology in human patients.


Pancreas ◽  
2021 ◽  
Vol 50 (3) ◽  
pp. 347-352
Author(s):  
Rui Zheng-Pywell ◽  
Amanda Fang ◽  
Ahmad AlKashash ◽  
Seifeldin Awad ◽  
Sushanth Reddy ◽  
...  

2020 ◽  
Vol 8 (1) ◽  
pp. e000415 ◽  
Author(s):  
Jahangir Ahmed ◽  
Louisa S Chard ◽  
Ming Yuan ◽  
Jiwei Wang ◽  
Anwen Howells ◽  
...  

BackgroundLocal recurrence and remote metastasis are major challenges to overcome in order to improve the survival of patients with cancer after surgery. Oncolytic viruses are a particularly attractive option for prevention of postsurgical disease as they offer a non-toxic treatment option that can directly target residual tumor deposits and beneficially modulate the systemic immune environment that is suppressed post surgery and allows residual disease escape from control. Here, we report that a novelVaccinia virus(VV), VVΔTKΔN1L (with deletion of both thymidine kinase (TK) and N1L genes) armed with interleukin 12 (IL-12), can prolong postoperative survival when used as a neoadjuvant treatment in different murine and hamster surgical models of cancer.MethodsA tumor-targeted replicating VV with deletion of TK gene and N1L gene (VVΔTKΔN1L) was created. This virus was armed rationally with IL-12. The effect of VVΔTKΔN1L and VVΔTKΔN1L-IL12 on modulation of the tumor microenvironment and induction of tumor-specific immunity as well the feasibility and safety as a neoadjuvant agent for preventing recurrence and metastasis after surgery were assessed in several clinically relevant models.ResultsVVΔTKΔN1L can significantly prolong postoperative survival when used as a neoadjuvant treatment in three different surgery-induced metastatic models of cancer. Efficacy was critically dependent on elevation of circulating natural killer cells that was achieved by virus-induced cytokine production from cells infected with N1L-deleted, but not N1L-intact VV. This effect was further enhanced by arming VVΔTKΔN1L with IL-12, a potent antitumor cytokine. Five daily treatments with VVΔTKΔN1L-IL12 before surgery dramatically improved postsurgical survival. VVΔTKΔN1L armed with human IL-12 completely prevented tumor recurrence in surgical models of head and neck cancer in Syrian hamsters.ConclusionsThese data provide a proof of concept for translation of the regime into clinical trials. VVΔTKΔN1L-IL12 is a promising agent for use as an adjuvant to surgical treatment of solid tumors.


2010 ◽  
Vol 25 (2) ◽  
pp. 36-38
Author(s):  
Syed Majid Hussain ◽  
Rauf Ahmad

Objective: Recurrence of a typical laryngeal carcinoid is extremely rare after surgery with tumor-free margins on histopathology. We present a rare case of typical laryngeal carcinoid that recurred after eight years and was managed by conservative surgery. Methods: Design: Case report  Setting: Tertiary Government Hospital Patient: One Results: A known case of typical laryngeal carcinoid treated eight years back reported again with the same symptoms he previously had. On evaluation local tumor recurrence was identified with a negative metastatic workup. The patient was subjected to microlaryngeal excision which was adequate histopathologically. He has had no evidence of disease on follow up of two years. Conclusion: A typical laryngeal carcinoid tumor may present differently and recur locally but conservative surgery is still an option if local nodal and distant metastatic spread is ruled out.  Key words: neuroendocrine tumor,typical laryngeal carcinoid, microlaryngeal excision. hemoptysis


Sign in / Sign up

Export Citation Format

Share Document